Evelo biosciences, inc. (EVLO)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17
Assets
Current assets:
Cash and cash equivalents

58,115

77,833

97,061

109,475

105,490

93,101

79,713

178,902

114,311

38,246

Short-term investments

-

-

0

3,998

23,949

54,818

84,615

-

-

0

Prepaid expenses and other current assets

2,878

3,176

4,170

3,825

3,843

3,703

3,711

1,974

876

531

Total current assets

60,993

81,009

101,231

117,298

133,282

151,622

168,039

180,876

115,187

38,777

Property and equipment, net

8,478

8,341

8,339

7,488

7,332

6,925

6,069

5,912

4,429

3,496

Right of use asset - operating lease

12,106

-

-

-

-

-

-

-

-

-

Other assets

1,570

1,570

1,570

1,422

1,320

1,320

1,498

1,500

2,697

1,515

Total assets

83,147

90,920

111,140

126,208

141,934

159,867

175,606

188,288

122,313

43,788

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable

1,210

620

1,358

2,693

1,379

1,519

2,880

2,679

1,367

1,411

Accrued expenses

9,039

8,758

7,919

6,914

5,237

4,965

5,561

4,684

2,950

2,199

Operating lease liability, current portion

1,806

-

-

-

-

-

-

-

-

-

Other current liabilities

408

365

398

282

4,600

2,751

972

154

300

229

Total current liabilities

12,463

9,743

9,675

9,889

11,216

9,235

9,413

7,517

4,617

3,839

Noncurrent liabilities:
Long-term debt

19,720

19,634

19,549

14,856

10,458

12,305

14,155

14,753

14,719

9,966

Operating lease liability, net of current portion

11,451

-

-

-

-

-

-

-

-

-

Deferred rent, net of current portion

-

1,148

1,146

1,123

1,097

1,071

941

890

1,023

478

Other noncurrent liabilities

169

198

224

252

280

307

337

80

701

526

Total liabilities

43,803

30,723

30,594

26,120

23,051

22,918

24,846

23,240

21,060

14,809

Commitments and contingencies

-

-

-

-

-

-

0

0

-

-

Temporary Equity, Carrying Amount, Attributable to Parent

-

-

-

-

-

-

0

-

165,778

83,702

Stockholder’s equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding at March 31, 2020 and December 31, 2019, respectively

0

0

0

0

0

0

0

0

-

0

Common stock, $0.001 par value; 200,000,000 shares authorized; 32,369,471 and 32,232,258 shares issued and 32,321,208 and 32,170,605 shares outstanding at March 31, 2020 and December 31, 2019, respectively

32

32

32

32

32

32

32

32

4

4

Additional paid-in capital

261,206

259,018

256,768

254,676

252,533

250,316

248,703

247,096

2,406

1,684

Accumulated other comprehensive loss

-

-

0

1

-2

-18

-38

-

-

0

Accumulated deficit

-221,900

-198,853

-176,300

-154,621

-133,680

-113,381

-97,937

-82,080

-66,935

-56,411

Total stockholders’ equity

39,344

60,197

80,546

100,088

118,883

136,949

150,760

165,048

-64,525

-54,723

Total liabilities and stockholders’ equity

83,147

90,920

111,140

126,208

141,934

159,867

175,606

188,288

122,313

43,788